The Philippines diabetes drugs and devices market size reached USD 755.85 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,684.41 Million by 2033, exhibiting a growth rate (CAGR) of 9.30% during 2025-2033. The Philippines diabetes drugs and devices market is driven by rising diabetes prevalence, increasing healthcare awareness, government initiatives improving access to treatment, technological advancements in glucose monitoring and insulin delivery, growing urbanization and sedentary lifestyles contributing to higher cases, and the expanding presence of pharmaceutical companies catering to local demand.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 755.85 Million |
Market Forecast in 2033 | USD 1,684.41 Million |
Market Growth Rate (2025-2033) | 9.30% |
Rising Prevalence of Diabetes
The rising incidence of diabetes in the Philippines contributes massively to the demand for drugs and equipment related to diabetes. As of recent reports, nearly 5% of the Philippines' adult population has diabetes mellitus. This increasing incidence can be explained by several factors, such as hectic lifestyles, physical inactivity, and dietary changes towards high-calorie, processed foods. The shift from traditional diets to Westernized diets has resulted in the rise in obesity rates, a significant risk factor for type 2 diabetes. The absence of regular physical activities among Filipinos also contributes to the increasing number of cases of the disease. The Department of Health (DOH) has also acknowledged the gravity of this condition and has been actively advocating for setting up Health Clubs in workplaces and communities since 2017. The clubs seek to promote healthy living and assist people at risk of or with diabetes. The increasing rate of diabetes patients requires a parallel increase in availability and access to diabetes control measures. This ranges from the spectrum of pharmacologic treatments, such as oral hypoglycemic drugs and insulin, to the array of medical devices such as glucometers and continuous glucose monitors. The healthcare system is, therefore, forced to respond, providing the public as well as the private sector with adequate capacity to serve the growing population. In addition, the cost of diabetes has significant economic implications, impacting not just the healthcare system but also productivity and quality of life. Overcoming this challenge calls for a complete package of public health interventions, policy changes, and ongoing product innovation and delivery of effective diabetes care products.
Government Initiatives and Policies
Different policies and programs by the Philippine government aimed at combating the increase in diabetes prevalence, thereby increasing demand for diabetes drugs and equipment. One such policy is the tax exemption on the sale of drugs for diabetes, hypertension, and cholesterol under the Tax Reform for Acceleration and Inclusion (TRAIN) Law. This program, which was initiated in January 2021, seeks to alleviate the economic burden on patients who need long-term medications, thus enhancing their access to appropriate treatments. Furthermore, the DOH has taken the initiative to develop and distribute Clinical Practice Guidelines (CPGs) that are intended to streamline and enhance the quality of diabetes care across the country. These suggestions assist healthcare professionals in making informed decisions about the diagnosis, management, and treatment of diabetes, ensuring that patients receive care grounded in evidence. The government's focus on enhancing healthcare infrastructure is equally important. Financial support for healthcare facilities, training of healthcare professionals, and awareness campaigns contribute to the timely identification and effective management of diabetes. These efforts improve patient outcomes and expand the market for diabetes-related goods as more individuals seek treatment and monitoring solutions.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region/country level for 2025-2033. Our report has categorized the market based on devices and drugs.
Devices Insights:
The report has provided a detailed breakup and analysis of the market based on the devices. This includes monitoring devices (self-monitoring blood glucose device and continuous blood glucose monitoring) and management devices (insulin pump, insulin syringes, insulin cartridges, and disposable pens).
Drugs Insights:
A detailed breakup and analysis of the market based on the drugs have also been provided in the report. This includes oral anti-diabetes drugs, insulin drugs, combination drugs, and non-insulin injectable drugs.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Luzon, Visayas, Mindanao.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Devices Covered |
|
Drugs Covered | Oral Anti-Diabetes Drugs, Insulin Drugs, Combination Drugs, Non-Insulin Injectable Drugs |
Regions Covered | Luzon, Visayas, Mindanao |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: